_1777294237270_124456903.png&w=48&q=75){kind=small}
Consultant Explains Weight Loss Methods
The article concludes that the General Authority for Food and Drug Administration has approved the oral medication "Fondaio" for the treatment of obesity. This medication contains the active ingredient orforglibron, which targets weight management in conjunction with a healthy diet and physical activity. The drug aims to help adults with obesity or overweight reduce their weight, particularly those with related medical conditions linked to excess weight. Studies indicate that Fondaio can lead to an average weight loss of 11.2% over 72 weeks, although results can vary depending on the study design and whether the participant has diabetes or not. The article also compares Fondaio to other medications such as "Semaglutide" and "Tirzepatide," clarifying that preferences depend on factors like the desired outcomes and patient adherence. Some patients prefer pills for their flexibility in timing, while others opt for weekly injections that may encourage better long-term compliance. Additionally, the importance of not directly comparing medication results without head-to-head clinical trials is highlighted, considering benefits like improvements in cardiovascular and kidney health, as well as common side effects such as nausea, diarrhea, and vomiting. Contraindications are also outlined, including allergy to the active substance, pregnancy, and thyroid tumors. The article concludes by emphasizing the importance of consulting a healthcare professional before starting treatment, noting that most patients tend to regain about two-thirds of the lost weight after stopping the medication.
Notice: This Is an AI-Generated Summary
Comments (0)